-
Ƶ appoints Laurence Reid and Brad Crutchfield to its Board of Directors
Cambridge, UK, 23 September 2024: Ƶ (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors. Bringing extensive commercial and leadership expertise to the Board, Laurence…
-
Ƶ appoints Steve Becker as Chief Commercial Officer
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Ƶ (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…
-
Ƶ joins Campus
Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…
-
Genomics company Ƶ expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park
Chesterford Research Park is delighted to welcome Ƶ to the Park’s eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Ƶ is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…
